戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 opathy, seizures, autonomic instability, and hyperkinetic movements.
2 ment disorder was observed in 3/21 patients: hyperkinetic movements (1), truncal ataxia (1) and dysto
3 : altered mental status (all), seizures (4), hyperkinetic movements (4), psychiatric features (3), me
4 orphism, progressive psychomotor disability, hyperkinetic movements, and axial hypotonia with variabl
5  variants of CAMK4 found in individuals with hyperkinetic movement disorder and comorbid neurological
6            Early-onset torsion dystonia is a hyperkinetic movement disorder caused by a deletion of o
7 lonus dystonia syndrome is a childhood onset hyperkinetic movement disorder characterized by predomin
8  individuals from two families affected by a hyperkinetic movement disorder due to homozygous mutatio
9                         A common form of the hyperkinetic movement disorder dystonia is caused by mut
10 isorder progresses, a complex hypertonic and hyperkinetic movement disorder is a common phenotype.
11                               The paroxysmal hyperkinetic movement disorder phenocopies a form of dys
12                                  Chorea is a hyperkinetic movement disorder resulting from dysfunctio
13 et torsion dystonia is an autosomal dominant hyperkinetic movement disorder that has recently been li
14      Myoclonus dystonia is a childhood-onset hyperkinetic movement disorder with a combined motor and
15 sion dystonia (ITD) is an autosomal dominant hyperkinetic movement disorder with incomplete penetranc
16 se in the first years of life to late-onset, hyperkinetic movement disorder with poor fine motor skil
17 atures, including central visual impairment, hyperkinetic movement disorder, and epilepsy or electroe
18 mental delay and/or intellectual disability, hyperkinetic movement disorder, transient elevation of t
19                   Dystonia is a debilitating hyperkinetic movement disorder, which can be transmitted
20 ormal, but developed ataxia and a paroxysmal hyperkinetic movement disorder.
21 pmental delay (often with regression), and a hyperkinetic movement disorder.
22 ologically dystonia most closely resembles a hyperkinetic movement disorder.
23 lanine has been described in patients with a hyperkinetic movement disorder.
24 recently identified in a family with a novel hyperkinetic movement disorder.
25 a residue that is mutated in patients with a hyperkinetic movement disorder.
26 ment (49%) to exercise intolerance (25%) and hyperkinetic movement disorders (41%), including dystoni
27 spose some individuals to the development of hyperkinetic movement disorders and seizures.
28 at endogenous mu agonists may play a role in hyperkinetic movement disorders by inducing sustained ac
29   The dystonias are a heterogeneous group of hyperkinetic movement disorders characterised by involun
30 s are still lacking, effective management of hyperkinetic movement disorders demands that physicians
31 therapy for the treatment of hypokinetic and hyperkinetic movement disorders has, however, led to an
32                                              Hyperkinetic movement disorders include tremors, dystoni
33  manifest in parkinsonism or a wide range of hyperkinetic movement disorders including chorea, ballis
34 man mutations in the PDE10A gene manifest in hyperkinetic movement disorders that phenocopy many feat
35 native diagnoses but atypical presentations (hyperkinetic movement disorders).
36 nt for medication-refractory hypokinetic and hyperkinetic movement disorders, and it is being explore
37 azine, show therapeutic efficacy in managing hyperkinetic movement disorders, including Huntington's
38  on studies in animal models and humans with hyperkinetic movement disorders, it is postulated that d
39 elated differences in PD and the most common hyperkinetic movement disorders, namely, essential tremo
40  treat medically intractable hypokinetic and hyperkinetic movement disorders, the course of the palli
41 ed to reverse these changes in patients with hyperkinetic movement disorders.
42 ovel therapeutic target for the treatment of hyperkinetic movement disorders.
43 , has been extended to the treatment of many hyperkinetic movement disorders.
44 e receptor blocker, is used to treat several hyperkinetic movement disorders.
45 e of pathogenic DRD2 variants in early-onset hyperkinetic movement disorders.
46 ectrum of antibodies accompanying autoimmune hyperkinetic movement disorders.
47 een shown to contribute to both epilepsy and hyperkinetic movement disorders.
48 lly targeted treatments for chorea and other hyperkinetic movement disorders.
49 ording of seizure activity in a patient with hyperkinetic movements during the seizure.
50              The occurrence of non-epileptic hyperkinetic movements in the context of developmental e
51 n the subthalamic nucleus (STN) results in a hyperkinetic movement syndrome, similar to the HD phenot